Is NMN Legal in Australia in 2026?

June 22, 2026

Yes, NMN can be supplied in Australia in 2026, but NMN products marketed as medicines must comply with Australian therapeutic goods requirements. NMN is now permitted for use as an active ingredient in listed medicines, subject to specific TGA requirements.

The Therapeutic Goods Administration (TGA) states that nicotinamide mononucleotide (NMN) was included in the Therapeutic Goods (Permissible Ingredients) Determination from 10 December 2025.

However, this does not mean that every NMN product sold online automatically complies with Australian requirements. Consumers should check the specific product, its ARTG information where applicable, dosage, directions and supplier information.

Official source: TGA — NAD, NAD+, NADH or NMN medicines sold in Australia

What Is NMN?

NMN stands for nicotinamide mononucleotide, a naturally occurring compound involved in the body's production of nicotinamide adenine dinucleotide (NAD+).

The TGA describes NMN as a metabolite of nicotinamide, which is a component of vitamin B3.

Interest in NMN has grown alongside research into NAD+ metabolism, cellular energy and healthy ageing. However, research into NMN continues to develop, and consumers should distinguish emerging scientific research from established therapeutic claims.

How Is NMN Regulated in Australia?

NMN is permitted for use as an active ingredient in listed medicines in Australia, but its use is subject to specific conditions.

According to current TGA information, requirements for NMN in listed medicines include:

NMN must be used as an active ingredient
The route of administration must be oral
The maximum recommended daily dose must not exceed 500 mg of NMN
The recommended duration of use must be 12 weeks or less
Specific sponsor requirements currently apply until 10 December 2027

The TGA has also published a compositional guideline defining quality specifications for NMN permitted for use in listed medicines.

Official source: TGA — Nicotinamide Mononucleotide Compositional Guideline

Does an NMN Product Need to Be Listed in the ARTG?

Medicines supplied in Australia generally need to be included in the Australian Register of Therapeutic Goods (ARTG), unless they are exempt or otherwise authorised.

For listed medicines, inclusion in the ARTG results in an AUST L number, which consumers can usually find on the product label.

This is an important distinction when evaluating NMN products available online. The fact that an overseas website ships an NMN product to Australia does not, by itself, establish that the product complies with Australian therapeutic goods requirements.

Is NMN TGA Approved?

The phrase “TGA approved” can be misleading when discussing an AUST L listed medicine.

Listed medicines are included in the ARTG after the sponsor certifies that the product meets applicable requirements. They are not individually evaluated by the TGA for quality, safety and efficacy before entering the market in the same way as registered medicines.

A standard listed medicine carries an AUST L number.

By comparison:

AUST L — listed medicine
AUST L(A) — assessed listed medicine
AUST R — registered medicine

Registered medicines undergo a higher level of pre-market TGA evaluation, while assessed listed medicines undergo pre-market assessment of evidence supporting their indications.

Therefore, when comparing NMN products, it is more accurate to check the product's ARTG status and AUST number rather than relying on a general statement that “NMN is TGA approved.”

What Does AUST L Mean on an NMN Product?

AUST L indicates that a listed medicine has been entered in the Australian Register of Therapeutic Goods.

Listed medicines are generally considered lower-risk medicines and can only use permitted ingredients and permitted low-level indications.

The sponsor must certify that the product meets the applicable regulatory requirements, and the TGA can conduct post-market compliance reviews.

An AUST L number therefore provides useful regulatory information, but consumers should not interpret it as meaning that the TGA individually tested or approved every claim made about the product before it entered the market.

How Can Consumers Check an NMN Product in Australia?

When considering an NMN product, Australian consumers can check:

Whether an AUST L, AUST L(A) or AUST R number appears on the label where applicable
The product's ARTG information
NMN amount per recommended daily dose
Directions for use
Required warnings
Ingredient information
Manufacturer and sponsor information
Quality and testing information provided by the brand

For an NMN listed medicine, the current TGA requirements concerning dosage, route of administration, duration of use and sponsor arrangements should also be considered.

How Much NMN Is Permitted in Australian Listed Medicines?

Under the current TGA requirements, the maximum recommended daily dose for a listed medicine containing NMN must not exceed 500 mg of nicotinamide mononucleotide.

The recommended duration of use must also be 12 weeks or less.

These are regulatory conditions applying to NMN as a permitted ingredient in listed medicines and should not be interpreted as personalised dosage advice.

Always follow the directions on the specific product label and seek advice from a healthcare professional when appropriate.

How to Choose an NMN Supplement in Australia

Regulatory status is only one consideration when comparing NMN supplements.

Consumers may also want to compare:

NMN purity and ingredient quality
Amount of NMN per serving
Formulation
Manufacturing standards
Testing and quality information
Storage requirements
Brand transparency

For a more detailed comparison, see:

For a broader quality-focused guide:

Frequently Asked Questions

Is NMN legal in Australia in 2026?

NMN is permitted for use as an active ingredient in Australian listed medicines, subject to specific TGA requirements. These currently include requirements concerning sponsorship, oral administration, maximum recommended daily dose and duration of use.

Can NMN be used in listed medicines in Australia?

Yes. NMN was included in the relevant Permissible Ingredients Determination from 10 December 2025 and may be used as an active ingredient in listed medicines when the applicable requirements are met.

What is the maximum NMN daily dose permitted for listed medicines?

The current TGA requirement states that the maximum recommended daily dose must not exceed 500 mg of NMN for listed medicines containing the ingredient.

Is NMN TGA approved?

It is more accurate to check the regulatory status of the specific product. Standard AUST L listed medicines are included in the ARTG but are not individually evaluated by the TGA for quality, safety and efficacy before market entry in the same way as registered medicines.

What does AUST L mean?

AUST L identifies a listed medicine included in the ARTG. Listed medicines must meet applicable regulatory requirements, although they do not undergo the same full pre-market evaluation as registered AUST R medicines.

How can I check an NMN product in Australia?

Check the product label for its AUST number where applicable and review the corresponding ARTG information, ingredients, dosage, directions, warnings and sponsor information.

Final Thoughts

NMN can be legally supplied in Australia within the applicable therapeutic goods framework, but consumers should evaluate the regulatory status of the individual product rather than assuming that every NMN product available online is compliant.

As of 2026, the TGA permits NMN as an active ingredient in listed medicines subject to specific requirements, including conditions relating to sponsorship, oral use, maximum recommended daily dose and duration of use.

When comparing NMN products, look for transparent regulatory information, clearly stated dosage and ingredients, appropriate manufacturing standards and realistic product claims.

Explore → NMN 500mg Supplement CellVive™ 60 Tablets | Enervite

Back to blog